Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (DE:9IP1)
MUNICH:9IP1
RESEARCH TOOLSreports
Rocket Pharmaceuticals (9IP1) Stock Price & Analysis
0 Followers
9IP1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€13.80 - €29.42
Previous Close€21.3
Volume0.00
Average Volume (3M)129.00
Market Cap
€1.98B
Enterprise Value€1.59B
Total Cash (Recent Filing)$437.17M
Total Debt (Recent Filing)$25.18M
Price to Earnings (P/E)N/A
Beta1.24
Next Earnings
May 08, 2024EPS Estimate
-€0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume129
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.33K
Enterprise Value/Ebitda-8.16
Forecast
1Y Price Target
€46.29Price Target Upside117.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Rocket Pharmaceuticals News
PremiumCompany Announcements
Rocket Pharmaceuticals Welcomes New CFO Aaron Ondrey
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentRocket Pharmaceuticals' participation at the prestigious Needham Healthcare Conference underlines its dedication to advancing gene therapies and engaging with the investment community.
Financial StabilityWith a strong cash balance providing runway into 2026, Rocket Pharmaceuticals is well-positioned to reach key milestones and transition into a commercial-stage company.
Regulatory MilestonesThe EMA's acceptance of RP-L102's MAA and the anticipated BLA submission to the FDA signal a significant step forward in Rocket's journey toward potential gene therapy approvals.
Bears Say
Financial PerformanceSG&A expenses were above estimates, suggesting higher than expected selling, general, and administrative costs.
Market EstimationThe addressable market for RP-A501 is likely smaller than the company's estimate.
Regulatory DelayKresladi's LAD-1 PDUFA was delayed due to an FDA bandwidth issue.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
2.60% Other Institutional Investors
97.40% Public Companies and
Individual Investors
9IP1 FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was €13.79 and its highest was €29.42 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Currently, no data Available
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is May 08, 2024 which is in 3 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Mar 07, 2024. The company reported -€0.597 earnings per share for the quarter, beating the consensus estimate of -€0.726 by €0.129.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -€0.63.
How many shares outstanding does Rocket Pharmaceuticals have?
Currently, no data Available
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -€0.597 in its last earnings report, beating expectations of -€0.726. Following the earnings report the stock price went up 3.211%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Among the largest hedge funds holding Rocket Pharmaceuticals’s share is Maverick Capital ltd. It holds Rocket Pharmaceuticals’s shares valued at 121M.
---
Rocket Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€46.29 (117.31% Upside)
€46.29 (117.31% Upside)
Blogger Sentiment
Bullish
DE:9IP1 Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $9.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.15%
12-Months-Change
Fundamentals
Return on Equity
-50.01%
Trailing 12-Months
Asset Growth
2.63%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
9IP1 Stock 12 Months Forecast
Average Price Target
€46.29
▲(117.31% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Adverum Biotechnologies
―
Crispr Therapeutics AG
―
Editas Medicine
―
Best Analysts Covering 9IP1
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+27.36%
reiterated a buy rating 3 months ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +27.36% per trade.
---